Compare Ascendis Pharma A/S (ASND) vs Yum! Brands, Inc. (YUM) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Ascendis Pharma A/S vs Yum! Brands, Inc. — how do they compare? Ascendis Pharma A/S trades at $270.99 (market cap $17.74B), while Yum! Brands, Inc. trades at $163.54 (market cap $45.08B). The key difference: Yum! Brands, Inc. is far larger — about 2.5× Ascendis Pharma A/S's market cap, and Yum! Brands, Inc. pays a 1.83% dividend while Ascendis Pharma A/S pays none. Which is the better fit depends on your goals.
| ASND | YUM | |
|---|---|---|
Market Cap | $17.74B | $45.08B |
Sector | Health | Consumer Cyclical |
52-Week High | $277.18 | $168.16 |
52-Week Low | $163.32 | $138.21 |
Enterprise Value | $18.11B | $56.34B |
Dividend Yield | — | 1.83% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ascendis Pharma (ASND) trades at $270.45, down 1.81% on the day, with a bullish technical outlook supported by moving averages and positive analyst sentiment. The company reported Q1 2026 revenue of $241 million (converted from €197 million for YORVIPATH and €44 million for SKYTROFA, Q1 2026 earnings report May 7, 2026) and beat EPS expectations, while recent news highlights clinical progress in achondroplasia and hypoparathyroidism treatments. Valuation ratios are elevated with a P/E of 31.38 and P/S of 16.94, reflecting growth expectations.
The outlook is positive due to strong revenue growth, multiple product launches, and a 92% analyst buy rating with a $321.17 price target. Key risks include high debt levels, persistent net losses despite improving margins, and reliance on successful commercialization of new therapies. The stock's upside depends on execution of growth strategy and achieving profitability.
YUM trades at $163.54, up 0.71% with bullish technical signals and strong support at $158. Revenue grew to $8.21B in 2025 with a 20.48% net margin, though profit margins have slightly declined. The recent $2.7B Pizza Hut sale and $4B buyback authorization highlight strategic focus on KFC and Taco Bell growth. Cash flow from operations remains robust at $2.01B, supporting dividend payments and debt management.
Outlook is positive with analyst consensus target of $174 offering 6.4% upside, but high debt levels and competitive pressures pose risks. The stock's valuation at 26.38 P/E requires sustained earnings growth to justify further gains, making execution on digital initiatives and international expansion critical near-term catalysts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Ascendis Pharma A/S
Ascendis Pharma A/S is a biopharmaceutical company. It develops prodrug therapies with profiles to address large markets with significant unmet medical needs with its Transcon technology. The firm's product pipeline includes Transcon growth hormone, Transconpeptides, Transcon PTH, Transcon CNP, and others. It operates mainly in North America, Germany, China, and Denmark and derives the majority of its revenue from China.
Read more on ASND →About Yum! Brands, Inc.
Yum Brands is a U.S.-based restaurant operator featuring a portfolio of four brands: KFC (26,930 global units), Pizza Hut (18,380 units), Taco Bell (7,790 units), and The Habit Burger (310 units) at year-end 2021. With $58 billion in 2021 systemwide sales, the firm is the second-largest restaurant company in the world, behind McDonald's ($112.5 billion) but ahead of Restaurant Brands International ($36 billion) and Starbucks ($25 billion). Yum is 98% franchised, with the largest franchisee, Yum China, created via a 2016 spinoff transaction (after which Yum China agreed to pay 3% royalties to Yum Brands in perpetuity). Yum is the newest evolution of Tricon Brands, formerly a division of PepsiCo, and generates the bulk of its revenue from franchise royalties and marketing contributions.
Read more on YUM →
